Citigroup’s Surface Oncology, Inc. Common Stock SURF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-37,657
| Closed | -$32.7K | – | 5855 |
|
|
2023
Q2 | $32.7K | Sell |
37,657
-1,008,500
| -96% | -$719K | ﹤0.01% | 4824 |
|
|
2023
Q1 | $731K | Hold |
1,046,157
| – | – | ﹤0.01% | 2819 |
|
|
2022
Q4 | $858K | Sell |
1,046,157
-615
| -0.1% | -$606 | ﹤0.01% | 2758 |
|
|
2022
Q3 | $1.09M | Sell |
1,046,772
-406
| -0% | -$649 | ﹤0.01% | 2648 |
|
|
2022
Q2 | $1.72M | Buy |
1,047,178
+1,044,658
| +41,455% | +$2.17M | ﹤0.01% | 2215 |
|
|
2022
Q1 | $7K | Sell |
2,520
-8,033
| -76% | -$28.2K | ﹤0.01% | 5715 |
|
|
2021
Q4 | $50K | Buy |
10,553
+4,071
| +63% | +$26.3K | ﹤0.01% | 5066 |
|
|
2021
Q3 | $49K | Sell |
6,482
-40,630
| -86% | -$260K | ﹤0.01% | 4747 |
|
|
2021
Q2 | $351K | Buy |
47,112
+29,864
| +173% | +$230K | ﹤0.01% | 3921 |
|
|
2021
Q1 | $135K | Sell |
17,248
-632
| -4% | -$6.32K | ﹤0.01% | 4224 |
|
|
2020
Q4 | $165K | Buy |
+17,880
| New | +$155K | ﹤0.01% | 5135 |
|
|
2020
Q1 | – | Sell |
-1,281
| Closed | -$2K | – | 7824 |
|
|
2019
Q4 | $2K | Buy |
1,281
+6
| +0.5% | +$10 | ﹤0.01% | 7567 |
|
|
2019
Q3 | $2K | Sell |
1,275
-428
| -25% | -$935 | ﹤0.01% | 7565 |
|
|
2019
Q2 | $5K | Sell |
1,703
-1,748
| -51% | -$6.96K | ﹤0.01% | 7492 |
|
|
2019
Q1 | $16K | Buy |
3,451
+1,067
| +45% | +$5.25K | ﹤0.01% | 7072 |
|
|
2018
Q4 | $10K | Buy |
2,384
+386
| +19% | +$2.98K | ﹤0.01% | 7167 |
|
|
2018
Q3 | $22K | Buy |
1,998
+954
| +91% | +$11.2K | ﹤0.01% | 7046 |
|
|
2018
Q2 | $17K | Buy |
+1,044
| New | +$15.1K | ﹤0.01% | 7004 |
|
Citigroup's SURF Position: Q3 2023 in Review
Citigroup sold out of Surface Oncology, Inc. Common Stock (SURF) in Q3 2023, closing a stake of 37,657 shares — an estimated $32.7K sold.
Citigroup first reported a position in SURF in Q2 2018 and held it in 18 quarters. The position peaked at $1.72M in Q2 2022. 0 funds tracked by Wall St. Rank hold SURF as of Q3 2023.
- Citigroup reported no remaining Surface Oncology, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Citigroup sold 37,657 Surface Oncology, Inc. Common Stock shares in Q3 2023, an estimated $32.7K.
- Citigroup first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 18 quarters.
- Citigroup's Surface Oncology, Inc. Common Stock position peaked at $1.72M in Q2 2022.
- 0 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2023.
Based on Citigroup's 13F filing for Q3 2023, filed 9 Nov 2023.